{"title":"The Effectiveness of <i>Perovskia abrotanoides</i> Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial.","authors":"Maryam Sadat Tayebi, Nazila Poostiyan, Masoud Sadeghi Dinani, Erfaneh Ghassami, Rasool Soltani","doi":"10.4103/jrpp.jrpp_13_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. <i>Perovskia abrotanoides</i> (Brazambel) has shown significant effects against <i>Leishmania</i> parasites in some studies. This study aimed to investigate the effects of <i>P. abrotanoides</i> extract topical formulation on cutaneous leishmaniasis.</p><p><strong>Methods: </strong>In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (<i>n</i> = 18) and control (<i>n</i> = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime<sup>®</sup>). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.</p><p><strong>Findings: </strong>The percentage of reepithelialization in the experimental group (4<sup>th</sup> week: 64.44 ± 25.13; 8<sup>th</sup> week: 83.85 ± 11.54) was higher than the control group (4<sup>th</sup> week: 53.97 ± 25.88; 8<sup>th</sup> week: 76.27 ± 21.67); however, the differences were not statistically significant (<i>P</i> = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).</p><p><strong>Conclusion: </strong>The use of <i>P. abrotanoides</i> extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071059/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_13_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. Perovskia abrotanoides (Brazambel) has shown significant effects against Leishmania parasites in some studies. This study aimed to investigate the effects of P. abrotanoides extract topical formulation on cutaneous leishmaniasis.
Methods: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.
Findings: The percentage of reepithelialization in the experimental group (4th week: 64.44 ± 25.13; 8th week: 83.85 ± 11.54) was higher than the control group (4th week: 53.97 ± 25.88; 8th week: 76.27 ± 21.67); however, the differences were not statistically significant (P = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).
Conclusion: The use of P. abrotanoides extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.
期刊介绍:
The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.